KIKUCHI, TETSURO,MAEDA, KENJI,GUY, GEOFFREY,ROBSON, PHILIP,STOTT, COLIN
申请号：
NZ58664808
公开号：
NZ586648A
申请日:
2008.12.17
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed herein is the use of tetrahydrocannabivarin (THCV) and/or cannabidiol (CBD), together with an atypical anti-psychotic medicament which is a dopamine-serotonin system stabilizer in the manufacture of a pharmaceutical formulation for use in the prevention or treatment of psychosis or a psychotic disorder, wherein the THCV and/or CBD are administered separately, sequentially or simultaneously to the atypical anti-psychotic medicament which is a dopamine-serotonin system stabilizer, so as to reduce or remove undesirable side effects of the atypical anti-psychotic medicament and / or provide additional anti-psychotic effects, wherein the atypical anti-psychotic medicament which is a dopamine-serotonin system stabiliser is aripiprazole or a metabolite of aripiprazole. Particularly preferred psychosis or psychotic disorders to be treated is taken from the group: schizophrenia schizophreniform disorder schizoaffective disorder bipolar I disorder bipolar II disorder major depressive disorder with psychotic feature delusional disorders Shared Psychotic Disorder Brief Psychotic disorder Psychotic disorder not otherwise specified paranoid personality disorder schizoid personality disorder and schizotypal personality disorder.
